anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To obtain a cold-polymerizable dental material capable of assuming a lifelike opalescence color by formulating a microfine titania as an opalescent agent therein. CONSTITUTION: This cold-polymerizable dental material comprises (A) a small amount of a polymerizable resin, preferably a mixture of diglycidyl methacrylate of bisphenol A with triethylene glycol dimethacrylate, (B) a large amount of an organic or an inorganic filler, e.g. a pulverized (meth)acrylate resin, silica or aluminum oxide, (C) a cold-polymerization initiator, e.g. a thermal initiator such as a peroxide or a photoinitiator such as an α-diketone and (D) an microfine titania having a smaller average particle diameter than half of the minimum wavelength of visible rays, i.e., &lt;=0.2μm, especially &lt;=0.6μm average particle diameter.  A value obtained by subtracting a value of ▵b* in a sample of a material having 1mm thickness without containing the component D from the value of ▵b* in a similar sample of the material, containing the microfine titania and having 1mm thickness is preferably &gt;15, especially &gt;20. The amount of the formulated component D is preferably 0.1-0.6wt.% in the case of a restorative and 0.05-2.5wt.% in the case of a cement.
PURPOSE: A fragment containing a human antibody which specifically binds to an extracellular soluble domain of DLK1 or antigen-binding site thereof is provided to prevent or treat metabolic diseases, immune diseases, or liver diseases. CONSTITUTION: A fragment contains a human antibody which specifically binds to extracellular soluble domain of DLK1(delta-like 1 homolog) or an antigen-binding site thereof. The domain contains an amino acid sequence of sequence number 1. The fragment containing the antigen-binding site is Fab, Fd, Fv, dAb, isolated CDR region, F(ab&#39;), F(ab&#39;)2, scFv or diabody. A method for preparing the fragment comprises: a step of preparing a recombinant vector containing a polynucleotide encoding the fragment; a step of transducing the recombinant vector to host cells to prepare a transformant; and a step of culturing the transformant. A pharmaceutical composition for preventing or treating cancer contains the fragment.
Biocompatible wear resistant nanostructured thin film materials are provided for application as coatings in the fabrication of load-bearing implants, for example, orthopedic and dental prosthetics, dental crowns, implants for maxillofacial surgery, artificial limbs, fixtures etc. Requirements to these materials include high hardness, fatigue resistance, wear and corrosion resistance, biocompatibility and absence of toxicity. The multicomponent nanostructured coating (MNC) has high hardness, low elastic modulus, high adhesion to the substrate, low friction coefficient and wear rate, high resistance to long elastic strain to failure and plastic deformation, low surface roughness, negative surface charge in physiological media (4.5&lt;pH&lt;9), bioactive surface, biocompatibility and absence of toxicity. Biocompatible multicomponent nanostructured coatings for load-bearing implants are synthesized on the basis of titanium carbonitride with the addition of elements that improve the mechanical and frictional properties of the coating and provide for its bioactivity, biocompatibility and absence of toxicity. The overall concentrations of the main and additional elements in the coating are in the following relationship: 1 , 2 &lt; ∑ X i ∑ Y j &lt; 20 , where Xi is the overall concentration of the main elements (Ti, C, N) in the coating and Yj is the overall concentration of the additional elements (Ca, Zr, Si, K, Mn, O, P) in the coating. The elemental concentration in the coating is chosen to keep the following component ratios, at. %: Ti:30-50, C:15-40, N:0.5-30, O:5-25, Ca:0-7, Zr:0-20, Si:0-30, P:0-1.5, Mn:0-1.0, K:0-1.0.
Improvements in the subject matter of principal patent no. 8603005 for: &#34;Process for the preparation of an 11- bromoeburnamenin&#34; The improvements made to patent no. 8603005 relate to the production of addition salts of 11-bromoeburnamenin, in particular its fumarate. The advantages of this in comparison with the 11-bromoeburnamenin base lie in the experimental finding that salts and more specifically the fumarate have greater solubility in water than the base, which offers better absorption by the body and more suitable bioavailability. The salts are obtained by reacting 11-bromoeburnamenin with an organic or inorganic acid in a polar solvent, such as ethanol or methanol, or in a halogenated solvent, such as chloroform or dichloromethane, at a temperature of between ambient temperature and the boiling point of the solvent. These compounds have application in the treatment of geriatric problems, on account of their vasodilatory and cerebral oxygenating properties.
The body has a number of sensitive surfaces that are subject to injury by physical, chemical and biological agents. The results of injury are, for example, signs of inflammation such as redness, swelling, feeling of heat, pain and loss of function, and discomfort such as itching, irritation, burning sensations, and dysesthesia. The nasal membranes, the ocular surface, the lips and gingiva, and the genital surfaces are examples of such sensitive surfaces. Topical agents can be delivered to these surfaces using pre-medicated single unit applicators, such as swabs, wipes, or cotton-tips attached to handles, but for high frequency use, there is an advantage to using a reservoir bottle of medicated solution together with a packet of single applicators. In this invention, an apparatus embodiment for topically delivering a pharmaceutical comprises a specially designed container, together with a package of single applicators. The desired parameters of drug delivery, namely, precise dosage, hygienic use and storage of the drug solution, single use, and economy for high frequency of use, are provided by the container design. The container accurately up-loads a fixed volume of solution onto the tip of a single applicator; wherein the tip of the applicator is made of an absorbent material such as cotton or rayon. The aperture or opening of the container has a cap that is air-tight when sealed. The diameter of the container aperture is not wider by more than 20% of the maximum width of the applicator tip. The container has a reservoir as an internal capacity to hold 5 to 50 mL of a liquid, and more preferably 5 to 15 mL. At the bottom of the container&#39;s reservoir there is a cylindrical cavity, the center of which is aligned perpendicularly to the center of the aperture. The lower wall of the container&#39;s reservoir is shaped to funnel the liquid contents of the container to the bottom of the cylindrical cavity formed as a reservoir pocket. This pocket has a concave upward, saucer like, or hemispheric shape to accommodate the tip of the applicator. The length of the container&#39;s cylindrical cavity is sufficient to sheath at least 50% of the body of applicator. This apparatus can up-load a single unit applicator with a low coefficient of variation in the up-loaded volume.
The invention relates to a compound treating diabetes and relevant complicating diseases and preparation method and application thereof. The invention provides the compound expressed as the formula X:The invention relates to a compound treating diabetes and relevant complicating diseases and preparation method and application thereof. The invention provides the compound expressed as the formula X: shown as the right, wherein R is -OH or R1COO&lt;-&gt;, R1 is C2-C20 carbon chain. The invention also provides the method for preparing the compound and a drug compound containing the compound shown as theshown as the right, wherein R is -OH or R1COO&lt;-&gt;, R1 is C2-C20 carbon chain. The invention also provides the method for preparing the compound and a drug compound containing the compound shown as theformula X. The invention also provides the application of the compound on preparing medicaments for treating diabetes and relevant complicating diseases. formula X. The invention also provides the application of the compound on preparing medicaments for treating diabetes and relevant complicating diseases.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cotton-like structure having such a shape as can easily closely adhere to the outer surface of an end-side anastomostic region, applicable to a micro blood anastomosis performed under microscopic operation, and having a function of gradually releasing an included medicament in the process of degradation and absorption of biodegradable polymers, and to provide a method of manufacturing the same.  &lt;P&gt;SOLUTION: The cotton-like structure for the circulatory organ is made of biodegradable polymers. The average fiber diameter is in the range from 100 nm to 10,000 nm, and the average apparent density is in the range from 10 to 95 kg/m&lt;SP&gt;3&lt;/SP&gt;. The cotton-like structure for the circulatory organ includes the medicament in the fiber. The method of manufacturing the cotton-like structure includes a step of manufacturing a solution by dissolving the biodegradable polymers and the medicament at the same time in a solvent; a step of applying the high voltage to the solution; a step of jetting the solution; a step of forming a fiber structure by evaporating the solvent from the jetted solution; a step of eliminating the charge of the formed fiber structure; and a step of accumulating the fiber structures by the elimination of the charge.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a recombinant Lactococcus strain with environmentally limited growth and viability.  &lt;P&gt;SOLUTION: The invention relates to a recombinant Lactococcus with environmentally limited growth and viability. It relates to the recombinant Lactococcus that can only survive in a medium, where specific medium components are present. A preferred embodiment is a Lactococcus that may only survive in a host organism, where such medium components are present, but cannot survive outside the host organism in the absence of such medium components. Moreover, the Lactococcus is transformed with a prophylactic and/or therapeutic molecules and used to treat deseases such as inflammatory bowel diseases.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention provides a new inclusion complexes which are stable in their so-lid state formed of SIN-1A and cyclodextrins or cyclodextrin derivatives and optionally also containing ions as catalyst or stabilizer. The complexes release nitric oxide at room temperature upon dissolving in water or aqueous systems. The ions are preferably carboxylic acid anions such as acetate, formiate, propionate, ascorbinate, tartarate and/or lactate and/or inorganic acid anions such as phosphate, phosphite, borate, carbonate, hydrocarbonate, sulfate, sulfite and/or cations such as alkali and/or ammonium. Pharmaceutical compositions as well as kits containing the complexes. The kits are to be used as NO-liberating standards to release NO in a predictable amount and rate on dissolving in aqueous media. Processes for the preparation of the complexes by subjecting at a suitable pH SIN-1 to the catalytic action of ions to shift the equilibrium towards formation of SIN-1A in the presence of cyclodextrins or cyclodextrin derivatives capable to form inclusion complexes, whereby the SIN-1A formed is immediately complexed and stabilized and isolating in the solid state the obtained new complexes optionally containing ions. A preferred process includes reacting SIN-1 and a cyclodextrin or cyclodextrin derivative in the solid state in the presence of a salt as a catalyst by thoroughly admixing or milling the components together or by freeze drying an aqueous, oxygen-free solution containing the components, followed preferably by &#39;&#39;second drying&#39;&#39; in vacuo.
X-ray contrast agents are provided in the form of tablets having a shaped core of a water-insoluble, powdery inorganic X-ray contrast substance and at least one binding agent, the core being coated with a layer of a basic foodstuff which is insoluble in water and does not swell or only swells slowly, and which is decomposed only in the presence of the corresponding enzymes.  The X-ray contrast substance may be bismuth silicate, barium silicate, silver iodide, barium sulphate or thorium oxide.  The binding agent may be starch, sugar, pectin, gum arabic.  The core may be isolated from the foodstuff layer by a soluble or easily decomposable layer, e.g. of sugar, pectin, milk sugar, dextrose, fruit sugar, mannite, water-soluble methyl cellulose, gum arabic, polyvinyl-pyrrolidone.  The foodstuff layer may be finally coated with a protective layer of sugar, milk sugar, dextrose, fruit sugar, pectin, starch sugar, &amp;c.  The foodstuff may be (i) a fat melting above 37 DEG C, e.g. beef- or mutton-tallow, hardened peanut-, cottonseed-palm-, whale- or rape-oil, propylene glycol distearate, glyceryl esters of fatty acids with a carbon chain of 16-20 carbon atoms obtained by oxidizing paraffins, or (ii) a protein, e.g. egg or serum albumin, or serum globulin rendered water-insoluble by heat or treatment with, e.g. formaldehyde, glyoxal or tannin, or fibrinogen treated with thrombin, or muscle protein which may have been subjected to heat-treatment, or (iii) a carbohydrate especialy various starches which may be mixed with dextrine, tragacanth, agar agar, gum arabic &amp;c. and, after application, heated to 100-140 DEG C.  The foodstuffs may contain preserving agents, and may be dyed for characterization.  Also the pills may have a shape characteristic of the particular foodstuff. Coating may be effected by dipping the pills in the foodstuffs in molten state or, dissolved or suspended in a liquid, or in a coating drum, or by spraying.  Fibrinogen and thrombin may be sprayed alternately.  One component may be applied in liquid form, and, another of the same foodstuff group, in powdered form.
Hair loss is a pressing concern that affects one&#39;s quality of life and even self-esteem, which is caused by heredity through genetic disposition and disparity of hormones. In order to deal with hair loss, consumers are seeking for remedies that are readily available in the market. However, these readily available remedies contain synthetic medications that impart adverse effects in the long run. With this, the interest for organic and natural remedies, such as Halal products, and with minimal environmental effect is on the rise. The formulation of bar shampoo using Halal ingredients addresses the hair loss problem that is faced by many, by imparting beneficial effects such as hair growth-promoting properties. The present utility model relates to a standardized process of producing a bar shampoo with hair growth promoting properties using Halal ingredients, through mixing of the halal ingredients to produce the desired bar shampoo.
PURPOSE: To provide a compd. which consists of a xanthine deriv. having action to suppress the activation of the lymphocytes of mammals and is useful as a treatment medicine for a autoimmune disease. CONSTITUTION: The 7-(oxoalkyl)1,3-dialkylxanthine exclusive of the Denbufylline of the formula (R&lt;1&gt; , R&lt;2&gt; are a 2 to 6C alkyl, cyclohexyl, alkoxyalkyl, hydroxyalkyl; A is a 1 to 4C hydrocarbon which may be substd. with methyl) is used for producing a lymphocyte activation suppressor. The compd. suppress the activation of &gt;=1 kinds of the lymphocytes selected from T helper cells, T cell damaging cell T suppressor cells, natural killer cells, killer cells which are the cause for cell damaging characteristics by interemediation of antibody dependent cells, T delay type irritable cells, B lymphocytes and groups consisting of the respective partial aggregates of these cell types.
PURPOSE:To provide the titled composition containing aluminum and carboxylic acid radical at a specific ratio in dissolved state, having a pH falling in a specific range, and effective to the prevention and remedy of hyperesthesia of dentin by contricting or blocking the dentinal tubule in the dentin. CONSTITUTION:The objective composition for oral cavity application contains aluminum and carboxylic acid radical in dissolved state at a molar ratio (carboxylic acid radical/aluminum) of &lt;=6, preferably 0.3/n-6/n (n is the number of carboxylic acid radicals), and has a pH of &gt;=5, preferably 5-10. The compound having carboxylic acid radical is the one having hydroxycarboxylic acid group, especially a hydroxymonocarboxylic acid compound such as lactic acid, glycolic acid, etc. The content of aluminum in the composition is preferably 0.01-10wt%, especially 0.1-5wt%. Addition of a phosphoric acid compound to the composition further improves the preventive and remedying effect. Similar improvement can be attained also by the combined use of oxalic acid and other carboxylic acid compound.
ABSTRACT      DIAGNOSTIC DEVICE INCORPORATING A BIOCHEMICAL LIGAND      The invention relates to a device useful in diagnostics in which a biochemical species is attached to the surface of a sensor, especially to the gate of a field effect transistor.  In such a &#34;BIOCHEMFET&#34; it has been a problem to attach two or more biochemical species to the surface of the sensor, especially to the gates of a multi-gated FET.  It has now been found possible to bond a group having a photoactivatable function covalently to the sensor surface, photo-expose the resultant modified surface selectively, e.g. through a mask, and bond the biochemical species, e.g. a hapten, antigen, antibody, lectin or enzyme, to the photoactivated function.  In this way the biochemical species becomes attached in selected areas only.  In view of the success of this technique realised under conditions of miniaturisation, the invention makes possible &#34;printed circuits for proteins&#34;.      The invention includes the device, process of manufacture thereo, use for diagnostic purposes and a diagnostic kit of the device and a partner capable of binding to the biochemical species.
PROBLEM TO BE SOLVED: To obtain the subject new compound having an Na&lt;+&gt; /H&lt;+&gt; exchange transfer system-inhibiting action and useful as a medicine for treating and preventing diseases caused by the sthenia of the exchange transfer system, such as hypertension, arrhythmia, stenocardia and cardiac hypertrophy. SOLUTION: A substituted guanidine derivative of formula I (R1 is H, an alkyl, a cycloalkyl, a cycloalkenyl, an aromatic group, etc.; R2 to R4 are each independently H, an alkyl, a cycloalkyl, a cycloalkenyl, a saturated heterocyclic group, a halogen, nitro, etc.; either one of Y1 to Y4 is methylene, carbonyl, an O atom, etc.; two of the others are each methylene, and the remaining is a single bond, methylene, etc.; Z is one or more of substituents which may arbitrarily be replaced with one or more of hydrogen atoms bound to the carbon atoms constituting the ring, each independently such as an alkyl or an alkenyl). For example, a compound of formula II. The compound of formula I is obtained e.g. by reacting a compound of formula III (L is a releasing group capable of being substituted by a nucleophilic group) with guanidine.
PURPOSE:To obtain a fibrous aggregate of micromolecules by dispersing an amphipatic substance contg. an amino acid residue represented by a specified general formula in distilled water and by carrying out ultrasonic treatment. CONSTITUTION:A fibrous aggregate of micromolecules made of a single kind of molecules and having amphipatic property comparable to that of natural lipid is produced by utilizing hydrogen bonding strength between amino acid residues and hydrophobic interaction between long chain alkyl groups. For example, a compd. represented by formula I [where X is halogen, (n) is an integer and R is 12-22C long chain alkyl] is dispersed in distilled water to about 10&lt;-5&gt;-10&lt;-1&gt;mol/l concn. and this dispersion liq. is subjected to ultrasonic treatment at about 70-80 deg.C to produce a fibrous aggregate of micromolecules. This aggregate capable of stably retaining its shape over a long time can be very easily obtd. from the high purity starting material as compared with a case using biolipid.
The present mvention discloses a novel pharmaceutical excipient for enhancing solubility of poorly water soluble drugs. The same is gum obtained from the bark of the plant Araucaria Cookii (Commonly known as &#39;Captain Cook&#39;s Pine&#39;) which is alcohol purified and air-dried to obtain free flowing powder. The powder can be easily compressed to formulate oral solid dosage forms e.g. tablets. Extraction of the crude gum with alcohol results in removal of impurities (Approx. 30% by weight) and yields a dry, free-flowing product (powder). The product has immense commercial importance because it results in enhanced bio-availability of poorly water soluble drugs, which in turns leads to better therapeutic profiles i.e. superior efficacy of the same drugs. The solubility enhancement of a poorly water soluble drug &#39;atorvastatin calcium&#39; when using the excipient of present invention was approximately 16 fold over the pure drug without excipient (Table 1).
It has been discovered that the stimulation of .beta.-adrenergic receptors, which activate cAMP formation, gives rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising .beta.-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by .beta.-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP).  Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of .beta.-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer&#39;s Disease.
The present invention discloses a stable polystyrene emulsion and a preparation method of the stable polystyrene emulsion, relating to the field of macromolecule synthesis materials. Styrene and water are mixed and stirred together according to the mass proportion rate from 1:10 to 1:5. Then beta-cyclodextrin or correspondent derivative which is 5 percent to 30 percent of the mass of the cinnamene is added into the solution. After that, potassium supersulphate  which is 1 percent to 3 percent of the mass of the cinnamene is added and nitrogen is popped in. The solution is heated to 70 DEG C to 80 DEG C for reaction for at least 8 hours. And then the solution is stopped from reaction and is stirred to cool to the room temperature. In this way, polystyrene emulsion is obtained. The polystyrene emulsion produced through the present invention is of no surfactant, organic solvent and inorganic salt. The polystyrene emulsion comprises beta-cyclodextrin or correspondent derivatives. According to the quality rate, the emulsion includes 8.8 percent to 16.5 percent polystyrene, 0.5 percent to 4.8 percent cyclodextrin or correspondent derivatives and 79.4 percent to 90.5 percent water. The cyclodextrin derivative is of the structure: R: 3 H or CH &lt;SUB&gt; &lt;/ SUB&gt;. The present invention is of fast reaction and short reaction time. No organic solvent is needed in the present invention. The emulsion generated through the present invention is of good stability.